… and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). This presentation will highlight the therapeutic …
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). Through now further developed design principles there …
… Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, … expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner … partnership is another validation of our leadership in ADAR-mediated RNA editing, our robust IP estate, and the …
… the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its … join the analyst Q&A session with the Management Team. Additionally, the following speakers will present at the …
… with the idea to hijack the endogenous RNA editing enzyme ‘ADAR’ in our cells and to redirect it to any target of … oligonucleotides that will go in to a cell and attract the ADAR enzymes to a particular site on the RNA that they want …
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic … A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic …
